Circulating tumor cells in breast cancer beyond the genotype of primary tumor for tailored therapy

International Journal of Cancer

Volumn 138, Issue 7, 2016, Pages 1586-1600

  Ren, Chuanli ^a,b   Han, Chongxu ^a   Fu, Deyuan ^a   Wang, Daxin ^a   Chen, Hui ^a   Chen, Yong ^a   Shen, Ming ^c  

^a CLINICAL MEDICAL COLLEGE OF YANGZHOU UNIVERSITY   (China)

^b Nanjing Medical University   (China)

^c YANGZHOU UNIVERSITY   (China)

Author keywords

breast cancer; circulating tumor cells (CTCs); TNM staging

Indexed keywords

TRASTUZUMAB; TUMOR MARKER;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CIRCULATING TUMOR CELL; DIAGNOSTIC ACCURACY; EPITHELIAL MESENCHYMAL TRANSITION; FLUORESCENCE IN SITU HYBRIDIZATION; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; MINIMAL RESIDUAL DISEASE; PRIMARY TUMOR; PRIORITY JOURNAL; REVIEW; ANIMAL; BLOOD; BREAST TUMOR; FEMALE; GENETICS; PATHOLOGY; PROCEDURES; TUMOR EMBOLISM;

ANIMALS; BREAST NEOPLASMS; FEMALE; GENOTYPE; HUMANS; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING;

EID: 84955649346     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29679     Document Type: Review

References (142)

1. Siegel R, Ma J, Zou Z, et al., Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Pivot X., Adjuvant chemotherapy for local relapse breast cancer. Lancet Oncol 2014; 15: 125-6.
3. Liu D, Long G, Mei Q, et al., Primary tumor volume should be included in the TNM staging system of nasopharyngeal carcinoma. Med Hypotheses 2014; 82: 486-7.
4. Pantel K, Brakenhoff RH, Brandt B., Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 2008; 8: 329-40.
5. Yap TA, Lorente D, Omlin A, et al., Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014; 20: 2553-68.
6. Rack B, Schindlbeck C, Juckstock J, et al., Circulating tumor cells predict survival in early average-to-high risk breast cancer patients. J Natl Cancer Inst 2014; 106. doi: 10.1093/jnci/dju066.
7. Maheswaran S, Haber DA., Ex vivo culture of CTCs: an emerging resource to guide cancer therapy. Cancer Res 2015; 75: 2411-2415.
8. Yu M, Bardia A, Aceto N, et al., Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science 2014; 345: 216-20.
9. Pantel K, Speicher MR., The biology of circulating tumor cells. Oncogene 2015. doi: 10.1038/onc.2015.192.
10. Ashworth A., A case of cancer in which cells similar to those in the tumours were seen in the blood after death. Aust Med J 1869; 14: 146.
11. Haber DA, Gray NS, Baselga J., The evolving war on cancer. Cell 2011; 145: 19-24.
12. Mehes G, Witt A, Kubista E, et al., Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001; 159: 17-20.
13. Aceto N, Bardia A, Miyamoto DT, et al., Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell 2014; 158: 1110-22.
14. Kallergi G, Konstantinidis G, Markomanolaki H, et al., Apoptotic circulating tumor cells in early and metastatic breast cancer patients. Mol Cancer Ther 2013; 12: 1886-95.
15. Ren C, Han C, Zhang J, et al., Detection of apoptotic circulating tumor cells in advanced pancreatic cancer following 5-fluorouracil chemotherapy. Cancer Biol Ther 2011; 12: 700-6.
16. Baccelli I, Stenzinger A, Vogel V, et al., Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget 2014; 5: 8147-60.
17. Zhang L, Ridgway LD, Wetzel MD, et al., The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci Transl Med 2013; 5: 180ra48
18. Chimonidou M, Kallergi G, Georgoulias V, et al., Breast cancer metastasis suppressor-1 promoter methylation in primary breast tumors and corresponding circulating tumor cells. Mol Cancer Res 2013; 11: 1248-57.
19. Alix-Panabieres C, Pantel K., Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 1-9.
20. Alix-Panabieres C, Schwarzenbach H, Pantel K., Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215.
21. Liu Z, Fusi A, Klopocki E, et al., Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients. J Transl Med 2011; 9: 70
22. Wu C, Hao H, Li L, et al., Preliminary investigation of the clinical significance of detecting circulating tumor cells enriched from lung cancer patients. J Thorac Oncol 2009; 4: 30-6.
23. Ran R, Li L, Wang M, et al., Determination of EGFR mutations in single cells microdissected from enriched lung tumor cells in peripheral blood. Anal Bioanal Chem 2013; 405: 7377-82.
24. Sun W, Huang T, Li G, et al., The advantage of circulating tumor cells over serum carcinoembryonic antigen for predicting treatment responses in rectal cancer. Future Oncol 2013; 9: 1489-500.
25. Karabacak NM, Spuhler PS, Fachin F, et al., Microfluidic, marker-free isolation of circulating tumor cells from blood samples. Nat Protoc 2014; 9: 694-710.
26. Chang CL, Huang W, Jalal SI, et al., Circulating tumor cell detection using a parallel flow micro-aperture chip system. Lab Chip 2015; 15: 1677-88.
27. Matsusaka S, Kozuka M, Takagi H, et al., A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid. Cancer Lett 2014; 355: 113-20.
28. Saucedo-Zeni N, Mewes S, Niestroj R, et al., A novel method for the in vivo isolation of circulating tumor cells from peripheral blood of cancer patients using a functionalized and structured medical wire. Int J Oncol 2012; 41: 1241-50.
29. Eifler RL, Lind J, Falkenhagen D, et al., Enrichment of circulating tumor cells from a large blood volume using leukapheresis and elutriation: proof of concept. Cytometry B Clin Cytom 2011; 80: 100-11.
30. Alix-Panabieres C, Pantel K., Challenges in circulating tumour cell research. Nat Rev Cancer 2014; 14: 623-31.
31. Alix-Panabieres C., EPISPOT assay: detection of viable DTCs/CTCs in solid tumor patients. Recent Results Cancer Res 2012; 195: 69-76.
32. Ntouroupi TG, Ashraf SQ, McGregor SB, et al., Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer 2008; 99: 789-95.
33. Ren C, He P, Zhang J, et al., Malignant characteristics of circulating tumor cells and corresponding primary tumor in a patient with esophageal squamous cell carcinoma before and after surgery. Cancer Biol Ther 2011; 11: 633-8.
34. Fehm T, Sagalowsky A, Clifford E, et al., Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002; 8: 2073-84.
35. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-15.
36. Giuliano M, Giordano A, Jackson S, et al., Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast Cancer Res 2014; 16: 440
37. Allard WJ, Matera J, Miller MC, et al., Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-904.
38. Neves RP, Raba K, Schmidt O, et al., Genomic high-resolution profiling of single CKpos/CD45neg flow-sorting purified circulating tumor cells from patients with metastatic breast cancer. Clin Chem 2014; 60: 1290-7.
39. Karhade M, Hall C, Mishra P, et al., Circulating tumor cells in non-metastatic triple-negative breast cancer. Breast Cancer Res Treat 2014; 147: 325-33.
40. Hartkopf AD, Stefanescu D, Wallwiener M, et al., Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. Breast Cancer Res Treat 2014; 147: 345-51.
41. Salvador J, Manso L, de la Haba J, et al., Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer. Clin Transl Oncol 2015; 17: 160-6.
42. Wallwiener M, Riethdorf S, Hartkopf AD, et al., Serial enumeration of circulating tumor cells predicts treatment response and prognosis in metastatic breast cancer: a prospective study in 393 patients. BMC Cancer 2014; 14: 512.
43. Smerage JB, Barlow WE, Hortobagyi GN, et al., Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 2014; 32: 3483-9.
44. Ignatiadis M, Riethdorf S, Bidard FC, et al., International study on inter-reader variability for circulating tumor cells in breast cancer. Breast Cancer Res 2014; 16: R43.
45. Talasaz AH, Powell AA, Huber DE, et al., Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci USA 2009; 106: 3970-5.
46. Müller V, Riethdorf S, Rack B, et al., Prognostic impact of circulating tumor cells assessed with the CellSearch System and AdnaTest Breast in metastatic breast cancer patients: the DETECT study. Breast Cancer Res 2012; 14: R118.
47. Markiewicz A, Ksiazkiewicz M, Welnicka-Jaskiewicz M, et al., Mesenchymal phenotype of CTC-enriched blood fraction and lymph node metastasis formation potential. PLoS One 2014; 9: e93901.
48. Mikulova V, Cabinakova M, Janatkova I, et al., Detection of circulating tumor cells during follow-up of patients with early breast cancer: clinical utility for monitoring of therapy efficacy. Scand J Clin Lab Invest 2014; 74: 132-42.
49. Weissenstein U, Schumann A, Reif M, et al., Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies. BMC Cancer 2012; 12: 206.
50. Parkinson DR, Dracopoli N, Petty BG, et al., Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med 2012; 10: 138.
51. Raimondi C, Gradilone A, Naso G, et al., Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011; 130: 449-55.
52. Mostert B, Kraan J, Sieuwerts AM, et al., CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 2012; 319: 49-55.
53. Serrano MJ, Ortega FG, Alvarez-Cubero MJ, et al., EMT and EGFR in CTCs cytokeratin negative non-metastatic breast cancer. Oncotarget 2014; 5: 7486-97.
54. Kim MS, Sim TS, Kim YJ, et al., SSA-MOA: a novel CTC isolation platform using selective size amplification (SSA) and a multi-obstacle architecture (MOA) filter. Lab Chip 2012; 12: 2874-80.
55. Nagrath S, Sequist LV, Maheswaran S, et al., Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007; 450: 1235-9.
56. Yoon HJ, Kim TH, Zhang Z, et al., Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol 2013; 8: 735-41.
57. Baccelli I, Schneeweiss A, Riethdorf S, et al., Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat Biotechnol 2013; 31: 539-44.
58. Kim DJ, Lee WY, Park NW, et al., Drug response of captured BT20 cells and evaluation of circulating tumor cells on a silicon nanowire platform. Biosens Bioelectron 2015; 67: 370-8.
59. Naume B, Borgen E, Beiske K, et al., Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 1997; 6: 103-14.
60. Wu S, Liu Z, Liu S, et al., Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions. Clin Chem Lab Med 2014; 52: 243-51.
61. Lustberg MB, Balasubramanian P, Miller B, et al., Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients. Breast Cancer Res 2014; 16: R23.
62. Hyun KA, Lee TY, Jung HI., Negative enrichment of circulating tumor cells using a geometrically activated surface interaction chip. Anal Chem 2013; 85: 4439-45.
63. Khoo BL, Warkiani ME, Tan DS, et al., Clinical validation of an ultra high-throughput spiral microfluidics for the detection and enrichment of viable circulating tumor cells. PLoS One 2014; 9: e99409.
64. Kim YJ, Koo GB, Lee JY, et al., A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads. Biomaterials 2014; 35: 7501-10.
65. Riahi R, Gogoi P, Sepehri S, et al., A novel microchannel-based device to capture and analyze circulating tumor cells (CTCs) of breast cancer. Int J Oncol 2014; 44: 1870-8.
66. Murlidhar V, Zeinali M, Grabauskiene S, et al., A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small 2014; 10: 4895-904.
67. Harouaka RA, Zhou MD, Yeh YT, et al., Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin Chem 2014; 60: 323-33.
68. Hyun KA, Kwon K, Han H, et al., Microfluidic flow fractionation device for label-free isolation of circulating tumor cells (CTCs) from breast cancer patients. Biosens Bioelectron 2013; 40: 206-12.
69. Yusa A, Toneri M, Masuda T, et al., Development of a new rapid isolation device for circulating tumor cells (CTCs) using 3D palladium filter and its application for genetic analysis. PLoS One 2014; 9: e88821.
70. Baker MK, Mikhitarian K, Osta W, et al., Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clin Cancer Res 2003; 9: 4865-71.
71. Balic M, Dandachi N, Hofmann G, et al., Comparison of two methods for enumerating circulating tumor cells in carcinoma patients. Cytometry B Clin Cytom 2005; 68: 25-30.
72. Papadaki MA, Kallergi G, Zafeiriou Z, et al., Co-expression of putative stemness and epithelial-to-mesenchymal transition markers on single circulating tumour cells from patients with early and metastatic breast cancer. BMC Cancer 2014; 14: 651.
73. Pachmann K, Camara O, Kavallaris A, et al., Quantification of the response of circulating epithelial cells to neodadjuvant treatment for breast cancer: a new tool for therapy monitoring. Breast Cancer Res 2005; 7: R975-9.
74. Tan SJ, Yobas L, Lee GY, et al., Microdevice for the isolation and enumeration of cancer cells from blood. Biomed Microdevices 2009; 11: 883-92.
75. Galletti G, Sung MS, Vahdat LT, et al., Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip 2014; 14: 147-56.
76. Farace F, Massard C, Vimond N, et al., A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas. Br J Cancer 2011; 105: 847-53.
77. Pinzani P, Salvadori B, Simi L, et al., Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. Hum Pathol 2006; 37: 711-8.
78. Lin HK, Zheng S, Williams AJ, et al., Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res 2010; 16: 5011-8.
79. Mohamed H, Murray M, Turner JN, et al., Isolation of tumor cells using size and deformation. J Chromatogra 2009; 1216: 8289-95.
80. Casavant BP, Mosher R, Warrick JW, et al., A negative selection methodology using a microfluidic platform for the isolation and enumeration of circulating tumor cells. Methods 2013; 64: 137-43.
81. Alix-Panabieres C, Vendrell JP, Pelle O, Rebillard, et al., Detection and characterization of putative metastatic precursor cells in cancer patients. Clin Chem 2007; 53: 537-9.
82. Ramirez JM, Fehm T, Orsini M, et al., Prognostic relevance of viable circulating tumor cells detected by EPISPOT in metastatic breast cancer patients. Clin Chem 2014; 60: 214-21.
83. Lu J, Fan T, Zhao Q, et al., Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients. Int J Cancer 2009; 126: 669-83.
84. Cho EH, Wendel M, Luttgen M, et al., Characterization of circulating tumor cell aggregates identified in patients with epithelial tumors. Phys Biol 2012; 9: 016001.
85. Marrinucci D, Bethel K, Bruce RH, et al., Case study of the morphologic variation of circulating tumor cells. Hum Pathol 2007; 38: 514-9.
86. Pachmann K, Clement JH, Schneider CP, et al., Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 2005; 43: 617-27.
87. Krivacic RT, Ladanyi A, Curry DN, et al., A rare-cell detector for cancer. Proc Natl Acad Sci USA 2004; 101: 10501-4.
88. Marrinucci D, Bethel K, Kolatkar A, et al., Fluid biopsy in patients with metastatic prostate, pancreatic and breast cancers. Phys Biol 2012; 9: 016003.
89. Kang JH, Krause S, Tobin H, et al., A combined micromagnetic-microfluidic device for rapid capture and culture of rare circulating tumor cells. Lab Chip 2012; 12: 2175-81.
90. Kim SJ, Masago A, Tamaki Y, et al., A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat 2011; 128: 765-73.
91. Aktas B, Bankfalvi A, Heubner M, et al., Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DX, clinicopathological markers and tumor cell dissemination in the blood and bone marrow. Mol Clin Oncol 2014; 1: 1049-54.
92. Warkiani ME, Guan G, Luan KB, et al., Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. Lab Chip 2014; 14: 128-37.
93. Liu H, Zhang X, Li J, et al., The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 2015; 141: 189-201.
94. Yu M, Bardia A, Wittner BS, et al., Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013; 339: 580-4.
95. Cheng M, Chen Y, Zou D, et al., The clinical utility of circulating tumor cells in breast cancer patients: detection by a quantitative assay of h-MAM gene expression. Int J Biol Markers 2014; 29: e268-78.
96. Ren C, Chen H, Han C, et al., Detection and molecular analysis of circulating tumor cells for early diagnosis of pancreatic cancer. Med Hypotheses 2013; 80: 833.
97. Lianidou ES, Strati A, Markou A., Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci 2014; 51: 160-71.
98. Wang HY, Ahn S, Kim S, et al., Detection of circulating tumor cell-specific markers in breast cancer patients using the quantitative RT-PCR assay. Int J Clin Oncol 2015.
99. Liu H, Zhang X, Li J, et al., The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells. J Cancer Res Clin Oncol 2015; 141: 189-201.
100. Cristofanilli M., Circulating tumour cells: telling the truth about metastasis. Lancet Oncol 2014; 15: 365-6.
101. Zhang L, Riethdorf S, Wu G, et al., Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012; 18: 5701-10.
102. Cristofanilli M, Budd GT, Ellis MJ, et al., Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-91.
103. Bidard FC, Peeters DJ, Fehm T, et al., Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol 2014; 15: 406-14.
104. Xenidis N, Perraki M, Apostolaki S, et al., Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer. Br J Cancer 2013; 108: 549-56.
105. Molloy TJ, Bosma AJ, Baumbusch LO, et al., The prognostic significance of tumour cell detection in the peripheral blood versus the bone marrow in 733 early-stage breast cancer patients. Breast Cancer Res 2011; 13: R61.
106. Daskalaki A, Agelaki S, Perraki M, et al., Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Br J Cancer 2009; 101: 589-97.
107. Xenidis N, Ignatiadis M, Apostolaki S, et al., Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer. J Clin Oncol 2009; 27: 2177-84.
108. Pierga JY, Bidard FC, Mathiot C, et al., Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008; 14: 7004-10.
109. Franken B, de Groot MR, Mastboom WJ, et al., Circulating tumor cells, disease recurrence and survival in newly diagnosed breast cancer. Breast Cancer Res 2012; 14: R133.
110. Nieto Y, Franklin WA, Jones RB, et al., Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biol Blood Marrow Transplant 2004; 10: 415-25.
111. Zach O, Kasparu H, Wagner H, et al., Prognostic value of tumour cell detection in peripheral blood of breast cancer patients. Acta Med Austriaca Suppl 2002; 59: 32-4.
112. Stathopoulou A, Vlachonikolis I, Mavroudis D, et al., Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002; 20: 3404-12.
113. Benoy IH, Elst H, Philips M, et al., Real-time RT-PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast cancer. Br J Cancer 2006; 94: 672-80.
114. Bidard FC, Mathiot C, Delaloge S, et al., Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 2010; 21: 729-33.
115. Ntoulia M, Stathopoulou A, Ignatiadis M, et al., Detection of mammaglobin A-mRNA-positive circulating tumor cells in peripheral blood of patients with operable breast cancer with nested RT-PCR. Clin Biochem 2006; 39: 879-87.
116. Giordano A, Giuliano M, De Laurentiis M, et al., Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. Ann Oncol 2012; 23: 1144-50.
117. Wallwiener M, Hartkopf AD, Baccelli I, et al., The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Breast Cancer Res Treat 2013; 137: 503-10.
118. Pierga JY, Hajage D, Bachelot T, et al., High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann Oncol 2012; 23: 618-24.
119. Giuliano M, Giordano A, Jackson S, et al., Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67.
120. Hayes DF, Cristofanilli M, Budd GT, et al., Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-24.
121. Budd GT, Cristofanilli M, Ellis MJ, et al., Circulating tumor cells versus imaging-predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-9.
122. Nakamura S, Yagata H, Ohno S, et al., Multi-center study evaluating circulating tumor cells as a surrogate for response to treatment and overall survival in metastatic breast cancer. Breast Cancer 2010; 17: 199-204.
123. Reinholz MM, Kitzmann KA, Tenner K, et al., Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group trials, N0234/336/436/437. Clin Cancer Res 2011; 17: 7183-93.
124. Nole F, Munzone E, Zorzino L, et al., Variation of circulating tumor cell levels during treatment of metastatic breast cancer: prognostic and therapeutic implications. Ann Oncol 2008; 19: 891-7.
125. Liu MC, Shields PG, Warren RD, et al., Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J Clin Oncol 2009; 27: 5153-9.
126. Tewes M, Aktas B, Welt A, et al., Molecular profiling and predictive value of circulating tumor cells in patients with metastatic breast cancer: an option for monitoring response to breast cancer related therapies. Breast Cancer Res Treat 2009; 115: 581-90.
127. Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, et al., Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol 2008; 19: 496-500.
128. Shiomi-Mouri Y, Kousaka J, Ando T, et al., Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Breast Cancer 2014 Jun 7. [Epub ahead of print]
129. Peeters DJ, van Dam PJ, Van den Eynden GG, et al., Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. Br J Cancer 2014; 110: 375-83.
130. Tryfonidis K, Boukovinas I, Xenidis N, et al., A multicenter phase I-II study of docetaxel plus epirubicin plus bevacizumab as first-line treatment in women with HER2-negative metastatic breast cancer. Breast 2013; 22: 1171-7.
131. Jiang ZF, Cristofanilli M, Shao ZM, et al., Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastatic breast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann Oncol 2013; 24: 2766-72.
132. Zhao S, Yang H, Zhang M, et al., Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Cell Biochem Biophys 2013; 65: 263-73.
133. Androulakis N, Agelaki S, Perraki M, et al., Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer. Br J Cancer 2012; 106: 1917-25.
134. Hayashi N, Nakamura S, Tokuda Y, et al., Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J Clin Oncol 2012; 17: 96-104.
135. McInnes LM, Jacobson N, Redfern A, et al., Clinical implications of circulating tumor cells of breast cancer patients: role of epithelial-mesenchymal plasticity. Front Oncol 2015; 5: 42.
136. Georgoulias V, Bozionelou V, Agelaki S, et al., Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study. Ann Oncol 2012; 23: 1744-50.
137. Meng S, Tripathy D, Shete S, et al., HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A 2004; 101: 9393-8.
138. Nadal R, Ortega FG, Salido M, et al., CD133 expression in circulating tumor cells from breast cancer patients: potential role in resistance to chemotherapy. Int J Cancer 2013; 133: 2398-407.
139. Heitzer E, Auer M, Gasch C, et al., Complex tumor genomes inferred from single circulating tumor cells by array-CGH and next-generation sequencing. Cancer Res 2013; 73: 2965-75.
140. Ren C, Chen H, Han C, et al., Increased plasma microRNA and CD133/CK18-positive cancer cells in the pleural fluid of a pancreatic cancer patient with liver and pleural metastases and correlation with chemoresistance. Oncol Lett 2012; 4: 691-4.
141. Ren C, Han C, Wang D, et al., Detection of circulating tumor cells: clinical relevance of a novel metastatic tumor marker. Exp Ther Med 2011; 2: 385-91.
142. Wallwiener M, Hartkopf AD, Riethdorf S, Nees J, Sprick MR, Schönfisch B, Taran FA, Heil J, Sohn C, Pantel K, Trumpp A, Schneeweiss A,. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. BMC Cancer 2015; 15: 403. doi: 10.1186/s12885-015-1423-6.